Skip to main content

Gastric Cancer News

Immunotherapy Effective Against Stomach Cancer

FRIDAY, June 6, 2025 — Immunotherapy combined with chemo can give people a fighting chance against stomach and esophageal cancers, a new clinical trial says. People treated with durvalumab and c...

ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer

THURSDAY, June 5, 2025 – For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) yields better...

Four-Gene Combo Might Predict Lethality Of Stomach Cancer

FRIDAY, April 25, 2025 — Four specific genes serve as a telltale clue to how potentially deadly stomach cancers will develop and progress, a new study says. Testing for these genetic mutations could e...

Guidelines Developed for Management of Gastric Premalignant Conditions

TUESDAY, March 25, 2025 – In a clinical guideline issued by the American College of Gastroenterology and published online March 12 in the American Journal of Gastroenterology, recommendations are ...

FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1)

On March 19, 2025, the Food and Drug Administration granted traditional approval to pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the...

Black Cancer Death Rate Declining, But Higher Risk Remains

FRIDAY, Feb. 21, 2025 – Cancer deaths among Black men and women in the U.S. have declined during the past decade in the United States, a new American Cancer Society (ACS) report says. The cancer...

Gastric Cancer Is a Considerable Health Concern Worldwide

MONDAY, Jan. 13, 2025 – Gastric cancer (GC) is a considerable health concern worldwide, especially among men and in East Asia, according to a study recently published in Cancer Biology & Medicine....

FDA Approves Subcutaneous Opdivo Qvantig for Most Solid Tumor Indications

FRIDAY, Jan. 3, 2025 – The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously approved adult, solid...

FDA Approves Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Subcutaneous Injection for Use in Most Previously Approved Solid Tumor Opdivo (nivolumab) Indications

PRINCETON, N.J.--(BUSINESS WIRE) December 27, 2024 – Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo Qvantig (nivolumab...

Tevimbra Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy

SAN MATEO, Calif.--(BUSINESS WIRE)-- December 27, 2024 – BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd.,...

FDA Approves Vyloy for Advanced Gastric or Gastroesophageal Junction Cancer

WEDNESDAY, Oct. 23, 2024 – The U.S. Food and Drug Administration has approved Vyloy (zolbetuximab-clzb) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line...

FDA Approves Vyloy (zolbetuximab-clzb) for the Treatment of Advanced Gastric and GEJ Cancer

TOKYO, Oct. 18, 2024 /PRNewswire/ – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved...

FDA Approves Hercessi (trastuzumab-strf), a Biosimilar to Herceptin

DURHAM, N.C., April 29, 2024 /PRNewswire/ – Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care...

FDA Approves Opdivo (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma Regardless of PD-L1 Expression Status

PRINCETON, N.J.--(BUSINESS WIRE)-- April 16, 2021 Opdivo is the first and only immunotherapy in combination with chemotherapy to deliver superior overall survival versus chemotherapy alone in a trial ...

FDA Approves Merck’s Keytruda (pembrolizumab) Combined With Trastuzumab and Chemotherapy as First-line Treatment in Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

KENILWORTH, N.J.--(BUSINESS WIRE) May 5, 2021-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Cancer

Related drug support groups

methotrexate, Keytruda, Herceptin, Opdivo, trastuzumab, docetaxel